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Chapter 9
Numerical Drugs for Calcium-Induced Calcium
Release
In the previous chapter, we developed models of calcium-induced calcium release
(CICR) in terms of both a stochastic release model and a model of the probability
density functions of the states involved in the stochastic release model. The models
incorporated the effects of mutations in both the ryanodine receptors (RyRs) and
the L-type calcium channels (LCCs). The purpose of the present chapter is to
introduce theoretical drugs aimed at repairing the effect of mutations of both the
LCCs and RyR channels. Model parameters used throughout this chapter are given
in Table 9.1.
We have seen in previous chapters that, if we ignore the effect of the LCC, we
can completely repair the effect of an RyR mutation using a closed state blocker
if the mutation is of the CO type. In this chapter, we want to see if this result also
holds when the effect of the LCCs is taken into account. Since the transmembrane
potential V enters the model as a parameter, it is sufficient to control the effect of
the LCCs for a number of different values of V . The next issue we want to address
is how to repair the effect of LCC mutations. We will find optimal open and closed
state blockers.
9.1 Markov Models for CICR, Including Drugs
We consider a situation where the RyR or the LCC may be affected by CO-
mutations. Both effects are modeled by Markov models and in this section we
introduce theoretical drugs in terms of open and closed state blockers for both the
RyR and the LCC.
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Table 9.1 Values of
parameters used in






9.1.1 Theoretical Blockers for the RyR
As discussed above, the gating of the release of calcium from the sarcoplasmic







Here  is the mutation severity index, which is one in the wild type case. We have














where Brc and B
r
o denote the blocked states associated with the closed and open
states, respectively. The characteristics of the drugs are given by the constants krcb




bo (for the open state blocker).
9.1.2 Theoretical Blockers for the LCC







where we have introduced the parameter  to indicate a mutation of the LCC. The
wild type case is again represented by  D 1 and any  > 1 denotes a leaky LCC.
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where, in line with the RyR case, Blc and B
l
o denote the blocked states associated
with the closed and open states, respectively, and the characteristics of the LCC
drugs are given by the constants klcb and k
l
bc (for the closed state blocker) and k
l
ob
and klbo (for the open state blocker).
9.1.3 Combined Theoretical Blockers for the LCC and the RyR
To use the probability density formalism, it is convenient to rewrite the two Markov
models as one combined model of the form illustrated in Fig. 9.1.This model
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Fig. 9.1 The Markov model
represented in Fig. 8.3
extended to account for
blockers for the LCC and the
RyR
B lcB rc B lcCr B lcOr B lcB ro
ClB rc ClCr ClOr ClB ro
OlB rc OlCr OlOr OlB ro
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9.2 Probability Density Functions Associated
with the 16-State Model
As mentioned in Chap. 7 (see page 119), it is convenient to use a more compact
notation to represent the system of partial differential equations governing the
probability density functions when the Markov model consists of numerous states.
By using the notation introduced in Chap. 7 , we can write the probability density














Rij D Ki;ji;jC1i;jC1 C Ki;jiC1;jiC1;j C Ki;ji;j1i;j1 C Ki;ji1;ji1;j


Ki;jC1i;j C KiC1;ji;j C Ki;j1i;j C Ki1;ji;j

i;j:
The flux terms are given by
axij D  ri vr .y  x/ C vd .c0  x/   lj Jl;
ayij D  ri vr .x  y/ C vs .c1  y/ ;
where  ri D 1 when the RyR state is open and  ri D 0 when the RyR state is closed
and similarly for  l and the LCC.
9.3 RyR Mutations Under a Varying Transmembrane
Potential
In this section, we assume that a mutation affects the RyR such that the mutation
severity index is increased. This problem has been discussed several times above,
but here we also need to take into account that the value of the transmembrane
potential may change. In our computations, we use  D 3 and we try to repair the
effect of the mutation by adding a closed state blocker to the Markov model of the
RyR channel. The Markov model is shown in Fig. 9.2.
The closed state drug applied to the RyR channel is represented by the two
parameters krcb and k
r
bc: We have seen above that for closed state blockers of the
RyR it is reasonable to define
krcb D .  1/ krbc;
where the value of krbc remains to be decided.
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Fig. 9.2 The Markov model represented in Fig. 8.3 extended to include an RyR mutation and a







































Fig. 9.3 Total probabilities based on the model for the probability density functions associated
with the Markov model in Fig. 9.2. A closed state blocker is applied, the mutation severity index
is  D 3, and the transmembrane potential is V D 0 mV. The plots show the total probability of
being in the state OO, (OC+OB), CO, or (CC+CB) as a function of krbc. In the upper left plot, the
total probability of being in the OO state is higher for the mutant than for the wild type. This is
repaired by the closed state drug. Similar results are shown for the other states
9.3.1 Theoretical Closed State Blocker Repairs the Open
Probabilities of the RyR CO-Mutation
Numerical results using the closed state drug shown in Fig. 9.2 are given in Fig. 9.3.
Note that we aim to repair the probability of being in the open state and are not













































Fig. 9.4 Based on the probability density functions of the states OO, (OC+OB), CO, and
(CC+CB), we can compute the expected concentrations of the dyad (x) and the JSR (y). The wild
type is denoted by ı and the RyR mutation index  increases from one to three along the solid
line. In the dashed line, we keep  D 3 and increase the value of krbc from 0 to 100 ms1. We
observe that as krbc increases, the expected concentrations are completely repaired. The experiment
is carried out for the case of V D 0 mV
interested in whether the channel is in a blocked state or in a closed state. The
probability of being in a closed or blocked state is therefore added in the graphs.
We observe from the graphs that the mutant channel is completely repaired by the
closed state blocker.
In Fig. 9.4, we show the development of the expected concentrations of the
dyad (x) and the junctional sarcoplasmic reticulum (JSR) (y) and observe that the
expected concentrations are repaired by a sufficiently strong version of the blocker
associated with the closed state of the RyR channel.
9.3.2 The Open State Blocker Does Not Work as Well
as the Closed State Blocker for CO-Mutations in RyR
In Table 9.2, we report on the performance of the open and closed state blockers for
the RyR mutation. Recall that the probability oo, the expected dyad concentration
(Exoo), and the expected JSR concentration (E
y
oo) are defined on page 72. The closed
blocker clearly is best suited to repair this mutation.
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Table 9.2 Properties of the probability density function (oo) of being in the state OO with  D 3
(and  D 1). The closed state blocker works fine in the sense that it is well suited for repairing a
CO-mutation of the RyR. The open state blocker is unable to completely repair the effect of the
mutation. The open state blocker is found using Matlab’s Fminsearch, with a cost function defined
to minimize the difference between the wild type and the mutation when the drug is applied. In
this table, WT and MT mean wild type and mutant, respectively, and V D 0 mV is used in the
simulations
WT MT Optimal closed blocker Optimal open blocker
103  oo 2:75 5:11 2:74 0:81
Exoo 51:87 45:62 51:92 52:46
Eyoo 751:76 544:30 751:99 713:89
Fig. 9.5 The Markov model
represented in Fig. 8.3
extended to include an LCC
mutation and a closed state
blocker for the LCC















Fig. 9.6 The Markov model
represented in Fig. 8.3
extended to include an LCC
mutation and an open state
blocker for the LCC
ClCr ClOr
OlCr OlOr













9.4 LCC Mutations Under a Varying Transmembrane
Potential
Next, we address the problem of defining a theoretical drug for LCC mutations. We
consider closed state LCC blockers of the form given in Fig. 9.5 and open state
blockers of the form given in Fig. 9.6.





































Fig. 9.7 Total probabilities based on the model for the probability density functions associated
with the Markov model in Fig. 9.5, where an LCC-type closed state blocker is included. The LCC
mutation severity index is  D 3 and the transmembrane potential is V D 0 mV. The plots show
the total probability of being in the state OO, OC, (CO+BO), or (CC+BC) as a function of klbc. In
the upper left plot, the total probability of being in the OO state is higher for the mutant than for the
wild type. This is repaired by the closed state drug. Similar results are shown for the other states
For the closed state blockers, we need to determine the two parameters klbc and




ob: For the closed
state blockers we define
klcb D .  1/ klbc
and we consider various values of klbc:
9.4.1 The Closed State Blocker Repairs the Open Probabilities
of the LCC Mutant
The results of applying the theoretical closed state blocker associated with the closed
state (see Fig. 9.5) of the LCC are given in Figs. 9.7, 9.8, and 9.9. In the first
figure, we show how the closed state blocker repairs the total probabilities and in the
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Fig. 9.8 Using the probability density functions of the states OO, OC, (CO+BO), and (CC+BC),
we compute the expected concentrations of the dyad (x) and the JSR (y). The wild type is denoted
by ı and the LCC mutation index  increases from one to three along the solid line. In the dashed
line, we keep  D 3 and increase the value of klbc from 0 to 100 ms1. We observe that as klbc
increases, the expected concentrations are completely repaired. The simulations are performed
using V D 0 mV
second figure we consider the expected concentrations. In Fig. 9.9, we show how the
expected concentrations are repaired for six values of the transmembrane potential.
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Fig. 9.9 The expected concentration of the dyad (x) and the JSR (y) for the OO state for the
transmembrane potential changing from 80 to 20 mV. The wild type is denoted by ı and the
LCC mutation index  increases from one to three along the solid line. In the dashed line, we keep
 D 3 and increase the value of klbc from 0 to 100 ms1. In all cases, the closed state blocker
repairs the effect of the mutation
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